Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EQPT
2076
EquipmentShare.com Inc
EQPT
$4.69B
| $1.11M | ﹤0.01% |
56,672
-359,967
| -86% | -$7.71M |
|
2077
Copart
CPRT
$31.3B
| $1.1M | ﹤0.01% |
39,142
+25,620
| +189% | +$827K |
|
2078
Vitesse Energy
VTS
$720M
| $1.1M | ﹤0.01% |
69,961
+36,439
| +109% | +$645K |
|
2079
PUT
EOG Resources
EOG
$80.3B
| $1.1M | ﹤0.01% |
8,500
-19,700
| -70% | -$2.68M |
|
|
ORKA
2080
Oruka Therapeutics
ORKA
$7.15B
| $1.1M | ﹤0.01% |
+11,586
| New | +$772K |
|
2081
Equillium
EQ
$146M
| $1.1M | ﹤0.01% |
344,409
-1,294,361
| -79% | -$3.1M |
|
2082
PRA Group
PRAA
$737M
| $1.1M | ﹤0.01% |
+58,005
| New | +$1.03M |
|
2083
Weis Markets
WMK
$1.76B
| $1.1M | ﹤0.01% |
14,061
-16,372
| -54% | -$1.2M |
|
2084
PUT
Plug Power
PLUG
$3.17B
| $1.1M | ﹤0.01% |
406,000
| – | – |
|
2085
Appian
APPN
$2.74B
| $1.09M | ﹤0.01% |
+47,684
| New | +$1.06M |
|
2086
PUT
Revolution Medicines
RVMD
$44.9B
| $1.09M | ﹤0.01% |
5,800
-44,200
| -88% | -$6.46M |
|
|
NSLR
2087
Neostellar Capital Corp
NSLR
$265M
| $1.09M | ﹤0.01% |
+86,594
| New | +$1.14M |
|
2088
Exelon
EXC
$45.1B
| $1.08M | ﹤0.01% |
23,268
+3,932
| +20% | +$182K |
|
2089
Martin Marietta Materials
MLM
$32.1B
| $1.08M | ﹤0.01% |
1,878
+978
| +109% | +$580K |
|
2090
Northern Trust
NTRS
$33.6B
| $1.08M | ﹤0.01% |
6,224
+1,980
| +47% | +$326K |
|
2091
Carter Bankshares
CARE
$724M
| $1.08M | ﹤0.01% |
31,801
+20,980
| +194% | +$568K |
|
2092
Surgery Partners
SGRY
$1.9B
| $1.08M | ﹤0.01% |
+64,377
| New | +$904K |
|
|
FCT
2093
DELISTED
First Trust Senior Floating Rate Income Fund II
FCT
| $1.08M | ﹤0.01% |
111,522
-100
| -0.1% | -$967 |
|
2094
Cyclerion Therapeutics
CYCN
$18.2M
| $1.08M | ﹤0.01% |
+317,511
| New | +$1.03M |
|
2095
SPS Commerce
SPSC
$2.92B
| $1.07M | ﹤0.01% |
18,717
-71,881
| -79% | -$3.97M |
|
2096
CALL
Cummins
CMI
$80.9B
| $1.07M | ﹤0.01% |
+1,500
| New | +$988K |
|
2097
Ralph Lauren
RL
$22.2B
| $1.07M | ﹤0.01% |
2,664
-98,915
| -97% | -$36.8M |
|
2098
PUT
Synchrony
SYF
$25.9B
| $1.06M | ﹤0.01% |
14,000
+5,200
| +59% | +$382K |
|
2099
CorVel
CRVL
$3.54B
| $1.06M | ﹤0.01% |
16,990
-13,222
| -44% | -$771K |
|
|
BNY
2100
Bank of New York Mellon
BNY
$108B
| $1.06M | ﹤0.01% |
+7,340
| New | +$1M |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.